Introduction
============

Noninvasive visualization of cystic lesions in the body has revolutionized the management of cystic echinococcosis (CE). Ultrasound (US) provides the clinician with important clinical information including the location, number, size and stage of cysts, with a higher sensitivity and specificity than serology. Portable US scanners have for the first time facilitated population screening. This screening allowed assessment of the true prevalence of disease in remote rural communities [@R0140-0001] [@R0140-0002] [@R0140-0003] . Currently US is the best method to assess the prevalence of CE due to the peculiar biological features of this parasitic disease in humans, to its portability and its acceptance by communities throughout the world. Furthermore, US is superior to CT or MRI for staging cysts [@R0140-0004] .

Cystic echinococcosis
=====================

Cystic echinococcosis, also known as hydatid disease or hydatidosis, is an infection caused by the larval stage (metacestode) of the cestode *Echinococcus granulosus.* In humans it may result in a wide spectrum of clinical manifestations ranging from asymptomatic infection to severe, even fatal disease.

*E. granulosus* has a broad geographic range and occurs on all continents including circumpolar, temperate, subtropical, and tropical zones. The highest prevalence of the parasite is found in parts of Eurasia, Africa, Australia, and South America.

Even within endemic zones, there is variation from high prevalence to sporadic infection, but only a few countries can be regarded as being free of *E. granulosus* .

Echinococcal cysts are found in the liver in approximately 70% of cases, and the lungs in approximately 25% of cases. The spleen, kidney, heart, muscle, bone and central nervous system are involved less frequently [@R0140-0005] .

In each anatomic site, cysts are surrounded by periparasitic host tissue (pericyst), which encompasses the larval endocyst. The endocyst has an outer, acellular laminated layer and an inner, or germinative, layer that gives rise to brood capsules and protoscolices.

The cyst is filled with clear fluid, numerous brood capsules and protoscolices. Cysts may also harbor daughter vesicles of variable size. Data is scarce regarding the growth and natural history of echinococcal cysts. The growth rate of the cysts is variable, with cyst diameter thought to increase on average 1 cm per year. Observational studies and unpublished experience gathered in referral centers suggest the natural history of CE. Changes to cyst structure occur in stages, which tend towards inactivity in a process that is favorable to the host. Early unilocular cysts (stage CE1) progress through stage CE3a to solidification of the cyst (CE4). Reactivation from stage CE3a can produce CE2 cysts, while reactivation from stage CE4 produces CE3b cysts. This has important consequences for screening and treatment, as CE2 and CE3b are generally non-responsive to non-surgical approaches.

Serious complications include mechanical complications due to mass effect either as compression of bile ducts with secondary cholestasis (common), or compression of vessels causing portal hypertension or Budd-Chiari syndrome (very rare). Liver infections can spread to the peritoneum with secondary echinococcosis and lung infections to pleural cavity in case of cyst rupture and spillage [@R0140-0006] . Cysts can rupture into the biliary system (common). Although rarely observed, anaphylactic shock can result from traumatic or other rupture of the cyst [@R0140-0007] [@R0140-0008] .

How are echinococcal cysts diagnosed?
=====================================

The diagnosis of CE is mainly made using imaging methods. For those cysts without pathognomonic signs, the adjunctive use of serology may be helpful. *E. granulosus* eggs are shed in feces passed by the definitive hosts, canids, but not by intermediate hosts. Therefore, direct parasitological diagnosis in humans is only possible through demonstration of viable protoscolices in the cyst, which can be obtained at surgery or by percutaneous aspiration. The latter cannot be performed routinely for technical and safety reasons, although the risk of anaphylaxis has been greatly exaggerated [@R0140-0009] .

Although US is the modality of choice for determining cyst stage and number and the extent of disease [@R0140-0010] , CT and MRI are valuable in certain circumstances previously described in detail [@R0140-0005] [@R0140-0011] [@R0140-0012] [@R0140-0013] and expanded upon below. US is the cornerstone of diagnosis, staging and follow-up of CE [@R0140-0006] .

Ultrasound
----------

US is the imaging modality of choice due to its availability, lack of radiation and high resolution for the diagnosis, staging, differential diagnosis and follow-up of most abdominal cystic lesions [@R0140-0012] [@R0140-0014] [@R0140-0015] . Moreover, it has an established role in the interventional treatment of CE [@R0140-0004] [@R0140-0006] . For field surveys, portable ultrasound is important as a screening tool [@R0140-0016] [@R0140-0017] [@R0140-0018] .

Computed tomography (CT)
------------------------

CT is indicated when US is unsatisfactory, particularly in obese patients or when visualization is difficult due to gas or bone [@R0140-0006] [@R0140-0019] . CT should also be considered to evaluate postoperative changes, suspicion of abdominal spillage, for better visualization of calcifications, in the event of air within the cyst and suspicion of biliary communication (MRI is the method of choice before endoscopic or surgical treatment). Historically CT has been the leading cross-sectional imaging method in the diagnosis and treatment of CE, but today MRI has been accepted as superior in many circumstances. CT provides invaluable clues for the assessment of complications and is indispensable in the diagnostic phase, for evaluating lung and bone. It is also important when there is diagnostic uncertainty on ultrasound, in planning surgical intervention, and diagnosing recurrent disease [@R0140-0019] [@R0140-0020] . Unenhanced CT is the modality of choice to assess calcifications. Calcification is not limited to inactive late stages but may be present in all stages, including, although only to a limited extent, early stages [@R0140-0013] . Contrast-enhanced CT is crucial in the differential diagnosis of focal liver lesions [@R0140-0021] . CT can also be used to guide PAIR in specific cases where US may be insufficient or provides inadequate visualization for intervention [@R0140-0012] [@R0140-0022] . PAIR stands for **p** uncture, **a** spiration, **i** njection of a scolecidal solution and **r** easpiration [@R0140-0023] [@R0140-0024] [@R0140-0025] .

Magnetic Resonance Imaging (MRI)
--------------------------------

MR cholangiography is preferred in complicated cases of communication or rupture into the biliary system. Additionally, MRI may be indicated when US is insufficient and CT is contraindicated. MRI has a high sensitivity for the detection of CE, particularly to assess the cyst number, size, location and relations to neighboring structures. MRI is indicated in patients in whom sonographic visualization is impaired because of bowel gas, obesity or previous surgical interventions, in disseminated disease, extra-abdominal location and complications. MRI is also useful for pre-surgical evaluation and follow-up [@R0140-0005] [@R0140-0026] . MRI with a T2-weighted sequence is better than CT for characterizing the internal structures of echinococcal cysts, reproducing better the ultrasound-defined features of CE [@R0140-0004] . MRI better visualizes the liquid areas inside the matrix [@R0140-0011] [@R0140-0026] and should be preferred for pre-treatment assessment whenever possible. MR cholangiography is as sensitive as endoscopic retrograde cholangiography (ERC) to evaluate cysto-biliary communications although it cannot be used for interventional procedures [@R0140-0026] [@R0140-0027] .

Conventional X-ray
------------------

Portable X-ray equipment has been used in field studies to look at the prevalence of deep-seated lung cysts that are inaccessible to US [@R0140-0028] , but they are rarely diagnosed in such surveys [@R0140-0028] [@R0140-0029] .

Serology
--------

Serologic tests are useful for confirming a presumptive imaging diagnosis. However, the limitations of sero-diagnosis in CE must be borne in mind to correctly interpret results. Moreover, it must be emphasized that serology should not be used alone for the diagnosis of CE in the absence of a compatible lesion identified by imaging, as the positive predictive value of sero-diagnosis is low [@R0140-0030] . Many variables influence the performance of sero-diagnostic tests. These include test-related factors (antigens used, assay technique), patient-related factors (immune status) and cyst-related factors (location, stage, size, number, previous therapy and complications) [@R0140-0031] [@R0140-0032] . Antigens used for the serological diagnosis of CE are not standardized, accounting for the extreme variability in reported diagnostic performance and the difficulty in comparing results from different groups. Generally speaking, tests based on hydatid cyst fluid (HCF) show a better sensitivity (sens. 80--99% and spec. 60--97%), while tests based on purified or recombinant proteins show a better specificity (sens. 38--93% and spec. 80--100%) [@R0140-0033] [@R0140-0034] . False-negative test results may occur in cases of hepatic CE with young CE1 cysts (30--58%), inactive CE4-CE5 cysts (50--87%), and in cases of extra-hepatic CE; including up to 50% of patients with lung cysts and patients with cysts in other locations. Patients with active and transitional cysts (CE2, CE3a, CE3b) show lower sero-negativity rates (5--20%), and patients with multiple cysts are generally sero-positive [@R0140-0031] [@R0140-0032] [@R0140-0035] [@R0140-0036] . Although cysts are classified as active (CE1, CE2, CE3b), transitional (CE3a) and inactive (CE4, CE5), the loss of integrity of the cyst structure (either spontaneous or as a consequence of therapy) rather than the biological viability (i. e. cyst activity) *per se* correlates with the presence of positive serology [@R0140-0031] . Serotiters are usually observed to increase in the months after medical or percutaneous treatments associated with disruption of cyst integrity, and slowly decrease over months or years after successful treatment [@R0140-0032] [@R0140-0037] [@R0140-0038] [@R0140-0039] . Serology may remain positive for years even after successful surgical treatment, limiting the use of serology to assess response to treatment, and leading the clinician to erroneously assume active infection and therefore to overtreat. Nonetheless, observing serotiters decrease over time (months to years) after treatment, or in the presence of inactive cysts, may provide an indication of cure [@R0140-0037] [@R0140-0038] [@R0140-0039] . Similarly, antibody titers generally increase upon relapse, although not universally [@R0140-0040] [@R0140-0041] . Assays detecting specific antibody classes or a number of recombinant proteins have been suggested to improve follow-up evaluation, [@R0140-0039] [@R0140-0040] [@R0140-0042] [@R0140-0043] . However, no such test is commercially available. False-positive results may occur in persons with other helminthic infections, especially in alveolar echinococcosis (AE) due to infection with *E. multilocularis* (50-100%) The different band pattern in HCF-based western blot may discriminate between *E. granulosus* and *E. multilocularis* in about 75% of cases [@R0140-0044] . However, more specific tests for *E. multilocularis* infection should be applied in case of high suspicion. Less frequently, false positives can be seen with other non-infectious diseases, such as cancer and chronic immune disorders [@R0140-0039] [@R0140-0045] [@R0140-0046] .

Ultrasound classification
=========================

There are various classifications of the sonographic appearance of CE, the first and most widely used being proposed by Gharbi in 1981 [@R0140-0047] . In 2003, the World Health Organization Informal Working Group on Echinococcosis (WHO-IWGE) proposed a standardized US classification based on the active-transitional-inactive status of the cyst as suggested by its sonographic appearance [@R0140-0014] .

The standardized classification scheme is intended to promote uniform standards of diagnosis and treatment and may be applied to the clinical treatment of patients as well as to field diagnostic surveys. In this classification, six cyst stages have been assigned to three clinical groups:

1.  The 'active' group includes developing cysts, which may be unilocular (CE1) or multi-vesicular with daughter vesicles (CE2) and which are usually found to be viable.

2.  The 'transitional' group (CE3) includes both cysts with detachment of endocyst (CE3a) and predominantly solid cysts with daughter vesicles (CE3b).

3.  The 'inactive' group (CE4 and CE5) exhibits involution and solidification of cyst content with increasing degrees of calcification and are nearly always found to be non-viable.

The WHO classification provides a rational basis for choosing an appropriate CE treatment scheme and follow-up, i. e. surgery, percutaneous treatment such as PAIR, benzimidazole chemotherapy or simply 'watch & wait'. The WHO classification recognizes two basic types of morphology for CE3: the 'water-lily sign' for floating membranes, which is now known as subclass CE3a, and predominantly solid cysts with daughter vesicles, or subclass CE3b. This subdivision has been proposed based on their different morphology and response to PAIR and albendazole, which is generally good for CE3a and poor for CE3b. A study using magnetic resonance spectroscopy has shown that these two subgroups have different metabolic profiles. Specifically, the metabolic profile of CE3b cysts is similar to that of viable (e.g.CE1 and CE2) stages, while cysts staged as CE3a can be either active or inactive. Importantly these results parallel studies examining biological viability evaluated microscopically after cyst removal [@R0140-0011] .

WHO Classification as an improved version of Gharbi classification
------------------------------------------------------------------

WHO-IGWE classification allows a grouping of cysts into active, transitional, and inactive, which is relevant for treatment planning and follow-up [@R0140-0006] . In this classification, CE1 and CE2 are active cysts, the CE3 group represents the transitional cysts with CE3b being biologically active [@R0140-0011] , while CE4 and CE5 groups are inactive, late stage cysts [@R0140-0014] . Importantly, Gharbi classification did not distinguish CE3b from CE4 cysts, which hampers a stage-specific approach to treatment. Another useful addition to Gharbi classification [@R0140-0047] is the "CL" category, indicating undifferentiated 'cystic lesions' that require further investigations before a definitive diagnosis can be made. Compared to Gharbi, the WHO-IWGE reverses the order of CE2 and CE3, subgrouping the CE3 lesions [@R0140-0006] [@R0140-0014] [@R0140-0048] . CE1 and CE3a are considered to be early stages [@R0140-0014] .

CL, as a potentially parasitic cyst, needs to be differentiated from non-parasitic cysts. This may also happen with CE1 cysts and CE3a [@R0140-0018] .

The WHO CE classification does not describe nor include terminology for the sequence of cyst involution seen spontaneously or induced by treatment [@R0140-0018] .

The WHO panels in detail
------------------------

The CE1 stage [Fig. 1](#FI0140-0001){ref-type="fig"} refers to a simple round or oval unilocular cyst with anechoic content and a visible double cystic wall. In early stages when the cysts are smaller than 4--5 cm and especially in children, the thick walls may not be seen. Therefore, differential diagnosis with simple liver or kidney cysts may sometimes be difficult.

![Appearance of a stage CE1 cyst. Ultrasound scan clearly demonstrates the double wall sign, pointing to the parasitic nature of the lesion.](10-1055-a-0650-3807-i0140-0001){#FI0140-0001}

The CE2 cyst is completely filled with daughter vesicles. What appears as "septa" are not true septa but the cyst walls of the daughter vesicles adjacent to one another [Fig. 2](#FI0140-0002){ref-type="fig"} .

![22-year-old man with CE2 cyst in the liver. The cyst is completely filled with daughter vesicles.](10-1055-a-0650-3807-i0140-0002){#FI0140-0002}

CE3 cysts includes two stages, CE3a and CE3b, which differ in terms of morphology, viability and clinical characteristics. CE3a is characterized by the "water-lily" sign, represented by floating membranes, i. e. the endocyst detached from the cyst outer wall (pericyst) [Fig. 3](#FI0140-0003){ref-type="fig"} . CE3b is a predominantly solid lesion with daughter vesicles [Fig. 4](#FI0140-0004){ref-type="fig"} and [Fig. 5](#FI0140-0005){ref-type="fig"} . CE3a may go on to become "solid" (inactive) or may give rise to daughter vesicles, in which case it becomes a CE2 cyst.

![Appearance of a stage CE3a cyst. Ultrasound demonstrates the detached, folded endocyst.](10-1055-a-0650-3807-i0140-0003){#FI0140-0003}

![A CE3b hydatid cyst in the right liver lobe of a 77-year-old man who has been followed for more than two years.](10-1055-a-0650-3807-i0140-0004){#FI0140-0004}

![Appearance of a stage CE3b cyst. Ultrasound scan reveals multiple daughter vesicles within the cyst.](10-1055-a-0650-3807-i0140-0005){#FI0140-0005}

US typically reveals coarse variable (hyper, hypo) echogenic echotexture without daughter vesicles. The "ball of wool" sign, corresponding to the detached endocyst as a hypoechoic folded structure embedded in a hyperechoic matrix, is the key US sign [Fig. 6](#FI0140-0006){ref-type="fig"} . However, often a definitive diagnosis of CE in this stage cannot be made by US findings alone. If CE4 stage is reached spontaneously, these cysts tend to remain inactive over time and, if asymptomatic, need only US monitoring [Fig. 7](#FI0140-0007){ref-type="fig"} [@R0140-0041] .

![Appearance of a stage CE4 cyst. Ultrasound scan shows the cyst content is uniformly echogenic.](10-1055-a-0650-3807-i0140-0006){#FI0140-0006}

![A 21-year-old male was referred for PAIR. The echinococcal cyst in the right liver lobe cyst in stage CE3a was smaller than 5 cm (approximately 35 cc) therefore treated with albendazole ( **a** ). After almost 6 years, the lesion was slightly smaller (30 cc) and had solidified ( **b** ).](10-1055-a-0650-3807-i0140-0007){#FI0140-0007}

CE5 cysts are partially (with an egg-shell calcified wall) or completely calcified with shadowing. These cysts are not viable in the vast majority of cases. Definitive diagnosis cannot be made by ultrasound findings alone [Fig. 8](#FI0140-0008){ref-type="fig"} .

![Appearance of a stage CE5 cyst. Ultrasound image of a CE5 cyst with the calcified rim clearly seen, together with a posterior acoustic shadowing.](10-1055-a-0650-3807-i0140-0008){#FI0140-0008}

The "CL" category indicates an undifferentiated 'cystic lesion' that requires further investigations before a definitive decision is made about their parasitic nature. As such, strictly speaking, CL is not a "stage" but rather a temporary label assigned to a cyst whose parasitic nature is still undefined. This is very helpful in ultrasound surveys in endemic areas when, for instance, the results of serological tests are still pending [Fig. 9](#FI0140-0009){ref-type="fig"} .

![Ultrasound shows 2 liver cysts (CL to the right) in a 43-year-old woman. CL is not a "stage" but rather a temporary label assigned to a cyst whose parasitic nature is still undefined.](10-1055-a-0650-3807-i0140-0009){#FI0140-0009}

US classification and serology: matches, mismatches and what to do about it
===========================================================================

The diagnosis of CE is mostly indirect and is based on imaging and serology. However, serology has several drawbacks as previously discussed: lack of standardization, cross-reactivity and antigen-dependent performance [@R0140-0033] [@R0140-0049] [@R0140-0050] , which depends also on cyst location and viability.

After ultrasound detection of a cyst with features compatible with CE but with no clear pathognomonic signs, a combination of diagnostic tests is recommended for confirmation (indirect hemagglutination (IHA), indirect immunofluorescence (IFAT), enzyme-linked immunosorbent assay (ELISA), and immunoblotting (IB)) [@R0140-0033] . In clinical practice, two tests are usually performed: ELISA (the more commonly used) and IHA. When results are inconclusive, IB can be performed as an additional test [@R0140-0005] [@R0140-0051] [@R0140-0052] [@R0140-0053] . Because of the high rates of false-negative results, especially in very early (CE1) and final stage cysts (CE4 and CE5), the role of serology is only confirmatory [@R0140-0018] . Serological testing in the context of liver involvement is more sensitive than for extrahepatic infections. The sensitivity of serological tests appears to be inversely related to the degree of sequestration of echinococcal antigens [@R0140-0010] .

Furthermore, current serology tests are not designed to clearly distinguish between active and inactive CE. In practice, problems arise mostly with early CE1 and late CE4/5 stages. The inverse problem can be faced in patients with inactive cysts, who should have negative serology but often are positive [@R0140-0041] [@R0140-0050] . Positive serology in these cases may be misleading when the patient has previously been treated.

Differential diagnosis of parasitic liver lesions
=================================================

Echinococcal cysts have to be differentiated from other conditions, such as non-parasitic cysts, single or multiple hemangiomas, pyogenic or amoebic liver abscesses, hematoma, and neoplasia with hemorrhage and necrosis (e. g., large adenoma, hepatocellular carcinoma, metastases, lymphoma), biloma and post-surgical sequelae and textiloma [@R0140-0005] [@R0140-0054] [@R0140-0055] . Most frequently, simple cysts are encountered but atypical cysts sometimes pose a diagnostic challenge. These include biliary cysts, polycystic liver disease, mucinous cystic neoplasms (cystic (biliary) adenoma, cystadenoma), cystic metastases and other very rare diseases, e. g., ciliated hepatic foregut cysts. Additionally other infectious agents must be considered: fungal, bacterial and amoebic abscesses [@R0140-0010] . In most uncertain cases, diagnosis should be achieved using aspiration. Only under particular circumstances, small and very large (\>50 mm), asymptomatic and uncomplicated simple cysts, may be monitored. This can be done by serial ultrasound at six-month intervals for the first two years following diagnosis. Significant growth, the development of progressive symptoms, or any suspicion of neoplastic change requires a definite diagnosis and surgical intervention. Other parasitic liver manifestations occasionally need to be considered in the differential diagnosis [@R0140-0056] [@R0140-0057] [@R0140-0058] .

Determining whether a cystic lesion is echinococcal depends on the presence of a double wall and is obvious when membrane detachment is present. Simple or minimally complex cysts, as well as biliary cystadenocarcinomas or abscesses, lack these features.

Treatment
=========

Ultrasound has a crucial role in the treatment of CE as a widely used means of guidance for percutaneous treatments. US is also crucial in the evaluation of treatment response (see below), and for assessing for inactivity in CE4 and CE5 asymptomatic liver cysts when managed expectantly, i. e. the so-called "watch and wait" approach [@R0140-0041] , due to the lack of ionizing radiation and repeatability.

PAIR is indicated for medium-sized CE1 and CE3a liver cysts [@R0140-0005] [@R0140-0048] . Recent EFSUMB guidelines on ultrasound-guided procedures [@R0140-0059] [@R0140-0060] list several abdominal ultrasound-guided treatment options [@R0140-0061] [@R0140-0062] .

CE2 and CE3b cysts are not responsive to PAIR [@R0140-0048] [@R0140-0063] . Although daughter vesicles can be punctured individually, these stages show growth of new daughter vesicles in the weeks following a procedure [@R0140-0005] [@R0140-0048] [@R0140-0064] . Successful drainage of the entire cyst content via large bore catheters has been reported in centers with specific expertise, but studies with larger cohorts of patients are needed to compare these methods with surgery [@R0140-0065] .

Before a PAIR procedure, the patient should have careful pre-procedure assessment. Albendazole should be started at least 4 h beforehand, as prophylaxis against secondary echinococcosis in case of inadvertent spillage of cystic fluid into the peritoneum, and continued for 1 month [@R0140-0006] [@R0140-0066] .

The puncture can usually be made by a 20-gauge fine needle but use of thinner or larger gauge needles has been reported [@R0140-0067] . Some authors use catheter drainage when cysts are bigger than 5-6 cm [@R0140-0068] [@R0140-0069] . Early studies on large-bore catheter evacuation of large cysts reported prolonged hospital stay and increased biliary complications [@R0140-0070] . However, catheter drainage is effective in selected cases, and when the required expertise is available [@R0140-0065] . If possible, a route through the hepatic parenchyma should be used to prevent peritoneal spillage of cyst contents. Usually all cystic content can be aspirated, before a scolicidal agent such as 96% ethanol or hypertonic (20%) saline is injected into the cavity [@R0140-0006] [@R0140-0059] [@R0140-0060] . The amount of scolicidal agent should not exceed ⅓ or ½ of the initial cyst volume. For cysts larger than 600 cc, a maximum amount of 200 cc is advised [@R0140-0006] . After 5--10 min, the fluid is re-aspirated [@R0140-0006] .

The patient should have IV access during the procedure and vital parameters should be monitored by an anesthesiologist or by a certified anesthesia nurse. Medications for the urgent treatment of anaphylaxis should be readily available [@R0140-0006] .

The cystic fluid is usually clear in early (CE1) cysts but the color may be dark yellow and the material viscous in later stages or infected cysts. The aspirated fluid should be examined under a microscope to assess for the presence of viable protoscolices [@R0140-0006] .

Evaluation and management of cystic communication with the biliary tree is debated. Commercially available dipsticks can immediately determine the presence of bilirubin in the aspirate. Some experts prefer cystography - that is injecting contrast material into the cyst cavity - to establish whether the cyst has a biliary connection. Most authors suggest that if the aspirate is not clear-colorless but contains bile, then scolecidal agents should not be given [@R0140-0024] . Others argue that hypertonic saline may be given with caution, and to date no biliary damage related to PAIR has been reported [@R0140-0005] .

In mid-sized CE1 and CE3a cysts, PAIR has an overall response rate \>80%, while multi-vesiculated CE2 and CE3b cysts have a success rate of less than 40% [@R0140-0065] . However, randomized, placebo-controlled clinical trials on the use of PAIR are lacking. A Cochrane review on PAIR with or without albendazole for the treatment of uncomplicated hepatic CE could evaluate only two randomized clinical trials comparing PAIR with either albendazole treatment alone or surgery and no other randomized trial has been published since. Both trials were small (30 and 50 patients, respectively), but graded as "adequate", and demonstrated a significantly better efficacy and lower morbidity than that of the treatments with which they were compared. The authors conclude that "PAIR with or without benzimidazole coverage may be comparable or superior to surgery or medical treatment with benzimidazoles alone for uncomplicated hepatic hydatid cysts", although "data are not sufficient to draw definitive conclusions" [@R0140-0071] .

After PAIR ultrasound, follow-up can be scheduled at one week, one month, three months, six months and then annually thereafter. CT may be necessary during follow-up and in cases with multiple cysts [@R0140-0071] [@R0140-0072] . US plays a crucial role in following the involution process resulting from treatment and in monitoring relapse (growth of new daughter vesicles) both after treatment and in the "watch and wait" approach [@R0140-0041] .

Conclusion
==========

Ultrasound allows diagnosis, differential diagnosis, treatment guidance and follow-up of CE. US has the additional role of a tool for mass screenings, which are currently the best way to assess the prevalence of CE in a population. Echinococcal cysts are predominantly observed in the liver where US is the best and easiest imaging modality. For lesions in the lungs, brain or other rare locations, CT and MRI are used. Although we have learned much from what US reveals and now have consensus on cyst types and stage-specific approach for hepatic cysts, the best treatment and follow-up algorithms remain a matter of debate.
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